BUSINESS● LOWSep 15 · Sep 15, 2026, 4:50 PM
Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy
Seeking Alpha Tech · global
Scholar Rock received a downgrade from Barclays, despite the recent FDA approval of its SMA therapy, indicating a divergence in market perception and regulatory success.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS38m agoDexcom anticipates $5.20B-$5.25B 2026 revenue while authorizing another $1B buybackSeeking Alpha TechBUSINESS38m agoFirst Internet Bancorp forecasts Q4 EPS of $1.02-$1.07 as it targets 2.75%-2.80% NIMSeeking Alpha Tech